



10 August 2022
NZX/ASX Market Release

Notice of deferral of FDA consideration of enforcement discretion

The a2 Milk Company (a2MC, the Company) wishes to advise that earlier today it received notification from the US Food and Drug Administration (FDA) that, at this time, the FDA is deferring further consideration of the Company's request for enforcement discretion to import infant milk formula (IMF) products into the US.

The Company has also subsequently been advised by the International Dairy Foods Association (IDFA) that equivalent letters have been sent to all pending enforcement discretion applicants, indicating that the FDA is deferring any further review at this time of all pending applications.

Authorised for release by

David Bortolussi
Managing Director and Chief Executive Officer
The a2 Milk Company Limited

For further information, please contact:

Investors / Analysts

David Akers
Group Head of Investor Relations and Sustainability
M +61 412 944 577
david.akers@a2milk.com

Rebecca Culbertson
Senior Analyst Investor Relations
M +61 400 955 295
rebecca.culbertson@a2milk.com

Media

Rick Willis
M +61 411 839 344
rick@networkfour.com.au

Media – New Zealand

Barry Akers
M +64 21 571 234
akers@senescallakers.co.nz